NICE backs Tobi Podhaler and Colobreathe for NHS use
Both the Tobi Podhaler (tobramycin) from Novartis and Colobreathe (colistimethate sodium) received backing to treat people with cystic fibrosis who have chronic pulmonary infection caused by Pseudomonas aeruginosa in final guidance published by the National Institute for Health and Clinical … Continued